VIR
Company Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 68.56M | 74.20M | 86.18M | 1.62B | 1.10B | 67.25M | 711,000 | 868,000 | 149,000 |
| Net Income | (437.99M) | (521.96M) | (615.06M) | 515.84M | 528.58M | (298.67M) | (174.68M) | (115.88M) | (69.85M) |
| EPS | -3.16 | -3.83 | -4.59 | 3.89 | 4.07 | -2.51 | -1.62 | -1.20 | -10.02 |
| Free Cash Flow | (396.61M) | (453.65M) | (800.36M) | 1.60B | (69.41M) | (197.49M) | (138.57M) | (102.29M) | (69.12M) |
| FCF / Share | -2.86 | -3.33 | -5.97 | 12.03 | -0.53 | -1.66 | -1.29 | -1.06 | -9.91 |
| Operating CF | (391.78M) | (446.35M) | (778.78M) | 1.66B | (47.59M) | (190.94M) | (129.63M) | (94.10M) | (66.38M) |
| Total Assets | 1.00B | 1.40B | 1.92B | 2.80B | 1.95B | 918.76M | 512.07M | 191.60M | 251.57M |
| Total Debt | 186.91M | 97.89M | 124.54M | 127.97M | 137.49M | 70.18M | 237,000 | 10.14M | 0 |
| Cash & Equiv | 234.11M | 222.95M | 241.58M | 848.63M | 347.81M | 436.57M | 109.33M | 47.60M | 187.92M |
| Book Value | 765.28M | 1.15B | 1.59B | 2.08B | 1.43B | 716.85M | 423.94M | (179.18M) | (68.92M) |
| Return on Equity | -0.57 | -0.45 | -0.39 | 0.25 | 0.37 | -0.42 | -0.41 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | (29,000) | 64.07M | 240,000 | 1.21M | 3.03M | 12.37M | 2.38M | 3.08M | 56.38M | 16.79M | 2.64M | 3.80M |
| Net Income | (125.69M) | (42.92M) | (163.14M) | (110.96M) | (120.97M) | (104.59M) | (213.72M) | (138.38M) | (65.28M) | (115.97M) | (163.41M) | (194.78M) |
| EPS | -0.85 | -0.31 | -1.17 | -0.80 | -0.88 | -0.76 | -1.56 | -1.02 | -0.48 | -0.86 | -1.22 | -1.45 |
| Free Cash Flow | (132.78M) | (21.39M) | (167.89M) | (122.76M) | (79.75M) | (90.04M) | (173.84M) | (78.51M) | (111.26M) | (109.46M) | (159.54M) | (398.70M) |
| FCF / Share | -0.90 | -0.15 | -1.21 | -0.89 | -0.58 | -0.66 | -1.27 | -0.58 | -0.82 | -0.81 | -1.19 | -2.97 |
| Operating CF | (132.39M) | (25.88M) | (167.57M) | (120.22M) | (78.12M) | (87.64M) | (171.48M) | (77.85M) | (109.39M) | (107.93M) | (155.83M) | (389.25M) |
| Total Assets | 1.03B | 1.00B | 1.02B | 1.19B | 1.31B | 1.40B | 1.50B | 1.67B | 1.79B | 1.92B | 2.04B | 2.24B |
| Total Debt | 86.64M | 186.91M | 100.17M | 102.23M | 96.09M | 97.89M | 112.81M | 114.51M | 121.08M | 124.54M | 127.68M | 131.35M |
| Cash & Equiv | 276.09M | 234.11M | 170.08M | 211.10M | 273.57M | 222.95M | 168.35M | 296.86M | 160.71M | 241.58M | 452.10M | 666.95M |
| Book Value | 812.76M | 765.28M | 796.10M | 947.47M | 1.04B | 1.15B | 1.24B | 1.43B | 1.55B | 1.59B | 1.68B | 1.81B |
| Return on Equity | -0.15 | -0.06 | -0.20 | -0.12 | -0.12 | -0.09 | -0.17 | -0.10 | -0.04 | -0.07 | -0.10 | -0.11 |
